牟健雄,沈彬

• 1:四川大学华西医院骨科
• 2:四川大学华西医院骨科 成都610041
• 3:成都610041

摘要(Abstract)：

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation): 四川省应用基础研究项目(No.05JY029-027-2)

作者(Author): 牟健雄,沈彬

参考文献(References)：

• [1]Fieisch H,Russell RGG,Straumann F.Effect of pyrophosphate onhydroxyapatite and its complications in calcium homeostasis[J].Na-ture,1966,212:901-903.
• [2]Ebetino FH,Francis MD,Rogers MJ,et al.Etidronate.Mechanism ofaction of etidronate and other bisphosphonates[J].Rev Contemp Phar-macol,1998,9:233-243.
• [3]Geddes AD,D Souza SM,Ebetino FH,et al.Bisphosphonates:struc-ture-activity relationships and therapeutic implications[J].Bone Min-er Res,1994,8:265-306.
• [4]Fleisch H,Russell RGG,Francis MD.Diphosphonates inhibithydroxyapaite dissolution in vitro and bone resorption in tissue cul-ture and in vivo[J].Science,1969,165:1262-1264.
• [5]Russell RGG,Muhlbauer RC,Bisaz S,et al.The influence of pyrophos-phate,condensed phosphates,pbospbonates and other phosphate com-pounds on the dissolution of hydroxyapatite in vitro and on bone re-sorption induced by parathyroid hormone in tissue culture and in thyro-parathyroidectomised rats[J].CalcifTissue Res,1970,6:83-196.
• [6]Chavassieux PM,Arlot ME,Reda C,et al.Histomorphometric assess-ment of the long-term effects of alendronate on bone quality and re-modeling in patients with osteoporosis[J].J Clin Invest,1997,100:1475-1480.
• [7]Saha H,Castren-Kortekangas P,Ojanen S,et al.Pharmacokinetics ofclodronate in renal failure[J].J Bone Miner Res,1994,9:1953-1958.
• [8]Hooper MJ,Ebeling PR,Roberts AP,et al.Risedronate prevents boneloss in early postmenopausal women:a prospective randomized,place-bo-controlled trial[J].Climacteric,2005,8(3):251-262.
• [9]Reginster JY,Adami S,Lakatos P,et al.Efficacy and tolerability ofonce-monthly oral ibandronate in postmenopausal osteoporosis:2-yearresults from the MOBILE study[J].Ann Rheum Dis,2006,26.
• [10]Hooper MJ,Ebeling PR,Robert AP,et al.Risedronate prevents boneloss in early postmenopausal women:a prospective randomized,place-bo-controlled triak[J].Climacteric,2005,8(3):251-262.
• [11]Reginster JY,Adami S,Lakatos P,et al.Patient preference for once-monthly oral ibandronate in postmenopansal osteoporosis:2-year re-sults from the MOBILE study[J].Ann Rheum Dis,2006,26.
• [12]Emkey R,Koltun W,Beusterien K,et al.Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized,open-label,cross-over trial:the Boniva Alendronate Trial in Osteoporo-sis(BALTO)[J].Curt Meal Res Opin,2005,21(12):1895-1903.
• [13]Iwamoto J,Takeda T,Sato Y,et al.Comparison of effect of treatmentwith etidronate and alendronate on lumbar bone mineral density in eld-erly women with osteoporosis[J].Yonsei Med J,200531,46(6):750-758.
• [14]Olszynski WP,Davison KS,loannidis G,et al.Effectiveness of alendr-onate and etidronate in the treatment of osteoporosis in men:a prospec-tive observational study[J].Osteoporos Int,2006,17(2):217-224.
• [15]van der Poest Clement E,Parka P,Vandormael K,et al.The effect ofalendronate on bone mass after distal forearm fraettre[J].J Bone Min-er Res,2000,15(3):586-593.
• [16]Bauman WA,Wecht JM,Kirshblum S,et al.Effect of pamidronate ad-ministration on bone in patients with acute spinal cord injury[J].Re-habil Res Dev,2005,42(3):305-313.
• [17]Hirayama T,Sabokbar A,Athanason NA.Effect of corticosteroids onhuman osteoclast formation and activity[J].J Endocrinol,2002,175(1):155-163.
• [18]Sato S,Ohosone Y,Suwa A,et al.Effect of intermittent cyclical etidr-onate therapy on corticosteroid induced osteoporosis in Japanese pa-tients with connective tissue disease:3 year follow-up[J].J Rheuma-tol,2003,30(12):2673-2679.
• [19]Ringe JD,Dorst A,Faber H,et al.Intermittent intravenous ibandronateinjections reduce vertebral fracture risk in corticosteroid-induced oste-oporosis:results from a long-term comparative study[J].OsteoporosInt,2003,14(10):801-807.
• [20]Loddenkemper K,Grauer A,Burmester OR,et al.Calcium,vitamin Dand etidronate for the prevention and treatment of corticosteroid-in-duced osteoporosis in patients with rheumatic diseases[J].Clin ExpRheumatol,2003,21(1):19-26.
• [21]Kanis JA,Borgstrom F,Johnell O,et al.Cost-effectiveness of raloxifenein the UK:an economic evaluation based on the MORE study[J].Os-teoporos Int,2005,16(1):15-25.
• [22]Nguyen ND,Eisman JA,Nguyen TV.Anti-hip fracture efficacy of bio-phosphonates:a Bayesian analysis of clinical trials[J].J Bone MinerRes,2006,21(2):340-349.
• [23]Felsenberg D,Miller P,Armbrecht G,et al.Oral iban~onate signifi-cantly reduces the risk of vertebral fractures of greater severity after1,2,and 3 years in postmenopausal women with osteoporosis[J].Bone,2005,37(5):651-654.
• [24]Bauer DC,Gamero P,Hochberg MC,et al.Pretreatment levels of boneturnover and the antifracture efficacy of alendronate:the fracture inter-vention trial,Bone Miner Res,2006,21(2):292-299.
• [25]Adachi JD,Rizzoli R,Boonen S,et al.Vertebral fracture risk reductionwith risedronate in post-menopausal women with osteoporosis:a recta-analysis of individual patient data[J].Aging Clin Exp Res,2005,17(2):150-156.
• [26]Frieder B,Graham R,Russell G.lbandronate in osteoporosis:preclini-cal data and rationale for intermittent dosing[J].Osteoporos lnt,2004,15:423-433.
• [27]Reid DM.Once-monthly dosing:an effective step forward[J].Bone,2006,38(4 Suppl 1):18-22.
• [28]Orcel P,Beaudreuil J.Bisphosphonates in bone diseases other than os-teoporosis[J].Joint Bone Spine,2002,69(1):19-27.
• [29]Licata AA.Risedronate,a novel pyridinyl bisphosphonate for the treat-ment of osteoporosis and Paget s disease of bone[J].Expert Opin ln-vestig Drugs,1999,8(7):1093-1102.
• [30]Ranch F,Travers R,Plotkin H,et al.The effects of intravenous pam-idronate on the bone tissue of children and adolescents with osteogena-sis imperfecta[J].J Clin Invest,2002,110:1293-1299.
• [31]Glorieux FH,Bishop NJ,Plotkin H,et al.Cyclic administration of pa-mindronate in children with severe osteogenesis imperfecta[J].NEnglJ Med,1998,339:947-952.
• [32]Zacharin M,Bateman J.Pamidronate treatment of osteogenasis imper-fecta:lack of correlation between clinical severity,age at onset of treat-ment,predicted collagen mutation and treatment response[J].J Pedi-atr Endocrinol Metab,2002,15:163-174.
• [33]Buyse G,Silberstein J,Goemans N,et al.Fibrodysplasia ossificans pro-gressiva:still turning into wood after 300 years[J].9 Eur J Pediatr,1995,154:694-699.
• [34]Hurvitz EA,Mandac BR,Davidoff G,et al.Risk factors for heterotopicossification in children and adolescents with severe traumatic brain in-jury[J].Arch Phys Med Rehabil,1992,73:459-462.
• [35]Silverman SL,Hurvitz EA,Nelson VS,et al.Rachitic syndrome afterdisodium etidronate therapy in an adolescent[J].Arch Phys Med Re-habil,1994,75:118-120.
• [36]Crawford BA,Karo C,Pavlovic J,et al.Zoledronic acid prevents boneloss after liver transplantation:a randomized,double-blind,placebo-controlled trial[J].Ann Intern Med,2006,21:144(4):239-248.
• [37]Mitterbauer C,Schwarz C,Haas M,et al.Effects of bisphosphonates onbone loss in the first year after renal transplantation-a meta-analysis ofrandomized controlled trials[J].Nephrol Dial Transplant,2006,30.
• [38]Chavassieux PM,Arlot ME,Reda C,et al.Histomorphometric assess-ment of the long term effects of alendronate on bone quality and re-modeling in patients with osteoporosis[J].J Clin Invest,1997,100:1475-1480.